
Commentary|Videos|February 12, 2025
Improving Clinical Trials Through Inclusion, Access, and Engagement
Fact checked by: Jordyn Sava
Mariam F. Eskander, MD, MPH, and Coral O. Omene, MD, PhD, discuss potential strategies that teams can implement to ensure clinical trials are more representative of the general population.
Advertisement
Mariam F. Eskander, MD, MPH, assistant professor of surgery and a gastrointestinal surgical oncologist at the Rutgers Cancer Institute, and Coral O. Omene, MD, PhD, an associate professor of medicine, breast medical oncologist, and program director for breast cancer disparities research at Rutgers Cancer Institute, discuss potential long-term, sustainable strategies that teams can implement to ensure clinical trials are more representative of the general population, and how that may differ between academic and community oncology settings.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Updated HARMONi Analysis Shows Consistent OS Benefit With Ivonescimab in EGFRm Lung Cancer
2
FDA Accepts NDA for Daraxonrasib in Metastatic Pancreatic Cancer
3
Community Clinical Trials and the Lung Cancer Pipeline
4
How Inherited BRCA Mutations Shape Breast Cancer's Genomic Behavior and Point Toward a New Treatment Paradigm
5




























